Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
用生物工程静脉芯片评估新冠病毒引起的静脉血栓形成的决定因素和靶向治疗
基本信息
- 批准号:10396569
- 负责人:
- 金额:$ 66.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVACE2AddressAdhesionsAmericanAnticoagulantsAnticoagulationApoptosisAttentionAttenuatedAutomobile DrivingAutopsyBiological AssayBiomedical EngineeringBloodBlood VesselsBlood coagulationCOVID-19COVID-19 patientCOVID-19 treatmentCellsCessation of lifeChinaClinical ResearchComplexComputational BiologyDataDeep Vein ThrombosisDevelopmentDevicesDiseaseDistalEndothelial CellsEndotheliumEnzyme Inhibitor DrugsExposure toGeometryHomeostasisHumanImmune responseInfectionInflammationInflammatoryInterdisciplinary StudyKidneyLeadLifeLower ExtremityLungMesenteryModelingMolecular BiologyOrganOutcomePathway interactionsPatientsPersonsPharmaceutical PreparationsPhysiologicalPlayPre-Clinical ModelPredispositionProteinsProteomicsResearchRespiratory FailureRoleSARS-CoV-2 infectionSavingsSignal PathwayStrokeStructureSurgeonTechniquesTechnologyTherapeuticTherapeutic Clinical TrialThrombosisTriad Acrylic ResinVeinsVenousVenous ThrombosisViralVirusVirus Diseasesclinical phenotypecombinatorialcoronavirus diseasecytokinedesigndifferential expressionendothelial dysfunctionhemodynamicsimprovedinnovationmechanotransductionnovelnovel coronavirusorgan on a chippreventreceptorrecruitresponsesevere COVID-19targeted treatmentthromboinflammationtranscriptometranscriptome sequencingvenous thromboembolism
项目摘要
ABSTRACT
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with
bioengineered Vein-Chip
Challenge: Increasing evidence shows that SARS-CoV-2, which is the novel coronavirus that causes COVID-
19, is able to trigger the formation of blood clots within the veins of patients. This ultimately manifests into strokes
and other life-threatening complications, being observed even in younger people. Related to that, is emerging
data that shows that the endothelial cells are dysfunctional across several organs other than the lungs of the
most severe COVID19 patients. These cells express the angiotensin-converting enzyme 2 (ACE2) receptor, to
which the virus attaches, using it as an entry point to infect cells. A recently created vein-on-a-chip (vein-chip)
that is an endothelialized organ-on-a-chip model incorporating the unique hemodynamics of the venous valve
cusp showed evidence that this model can be used to dissect the role of major determinants of venous
thrombosis – endothelium; hemodynamics; and blood components – together known as the Virchow's
triad. The central hypothesis in this proposal is that the venous thrombosis observed in COVID19 disease is due
to the interaction of the three determinants of thrombosis (Virchow's triad) – endotheliitis; complex
hemodynamics; and blood coagulability. There is an unmet need to understand the effects of the virus and/or
blood-borne inflammatory cytokines on the endothelium; and the interaction of these effects with the uniquely
complex venous hemodynamics (mechanotransduction); and to discover strategies to stabilize the endothelium
that may be co-operatively therapeutic with anticoagulants.
Proposal: The objective here is to deploy vein-chip technology to understand the determinants of SARS-CoV-
2 induced venous thrombosis; determine the roles of endothelial, hemodynamic and humoral alterations; and
propose therapeutic strategies. This objective will be met through three specific aims: Aim 1: Characterize the
SARS-CoV-2 induced endothelial dysfunction in the human Vein-Chip; Aim 2: Assess interplay of SARS-CoV-2
infection and hemodynamics in DVT with Vein-Chip, and Aim 3: Therapeutics-on-Chip: Assess
combinatorial therapeutics in infection-led DVT with Vein-Chip. The team driving this proposal is composed of
complementary expertise in vein-chip bioengineering and innovation (Jain); applying contemporary technology
in the molecular and computational biology of endothelial function and fate (Cooke); together with techniques to
define host response to coronaviral infection (Connor).
Impact: Taken together, the outcomes of this proposal will directly improve our understanding of thrombosis in
COVID-19 infection and make predictions that could potentially result in fast-tracking of therapeutic clinical trials.
摘要
COVID 19诱导的静脉血栓形成的决定因素和靶向治疗评估
生物工程静脉芯片
挑战:越来越多的证据表明,SARS-CoV-2是导致COVID-19的新型冠状病毒,
19,能够触发患者静脉内血栓的形成。最终表现为中风
以及其他危及生命的并发症,甚至在年轻人中也能观察到。与此相关的是,
这些数据表明,内皮细胞在除肺以外的几个器官中功能失调,
最严重的COVID 19患者。这些细胞表达血管紧张素转换酶2(ACE 2)受体,
病毒附着在上面,以此作为感染细胞的切入点。最近创建的静脉芯片(静脉芯片)
这是一个内皮化的器官芯片模型,
Cusp表明,该模型可用于解剖静脉血栓形成的主要决定因素的作用,
血栓形成-内皮;血液动力学;和血液成分-一起被称为魏尔啸的
三和弦该提案的中心假设是,在COVID 19疾病中观察到的静脉血栓形成是由于
血栓形成(魏尔啸三联征)-内皮炎的三个决定因素的相互作用;复杂
血液动力学和血液凝固性。有一个未满足的需要,了解病毒的影响和/或
血液传播的炎症细胞因子对内皮细胞的影响;以及这些影响与独特的
复杂的静脉血流动力学(机械转导);并发现稳定内皮的策略
可以与抗凝剂协同治疗。
建议:这里的目标是部署静脉芯片技术,以了解SARS-CoV的决定因素,
2诱导静脉血栓形成;确定内皮、血流动力学和体液改变的作用;和
提出治疗策略。将通过三个具体目标实现这一目标:
SARS-CoV-2诱导人静脉芯片内皮功能障碍;目的2:评估SARS-CoV-2的相互作用
静脉芯片治疗DVT的感染和血流动力学,目标3:芯片治疗:评估
静脉芯片治疗感染性深静脉血栓的组合疗法推动这一提案的团队由以下人员组成:
静脉芯片生物工程和创新方面的互补专业知识(Jain);应用当代技术
在内皮功能和命运的分子和计算生物学(库克);连同技术,
定义宿主对冠状病毒感染的反应(康纳)。
影响:总的来说,这项提案的结果将直接提高我们对血栓形成的理解,
COVID-19感染,并做出可能导致治疗性临床试验快速跟踪的预测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN P COOKE其他文献
JOHN P COOKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN P COOKE', 18)}}的其他基金
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
用生物工程静脉芯片评估新冠病毒引起的静脉血栓形成的决定因素和靶向治疗
- 批准号:
10199360 - 财政年份:2021
- 资助金额:
$ 66.53万 - 项目类别:
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip
用生物工程静脉芯片评估新冠病毒引起的静脉血栓形成的决定因素和靶向治疗
- 批准号:
10617651 - 财政年份:2021
- 资助金额:
$ 66.53万 - 项目类别:
Reversal of Heart Failure: Role of Vascular Recovery
逆转心力衰竭:血管恢复的作用
- 批准号:
10215614 - 财政年份:2020
- 资助金额:
$ 66.53万 - 项目类别:
Reversal of Heart Failure: Role of Vascular Recovery
逆转心力衰竭:血管恢复的作用
- 批准号:
10397100 - 财政年份:2020
- 资助金额:
$ 66.53万 - 项目类别:
Reversal of Heart Failure: Role of Vascular Recovery
逆转心力衰竭:血管恢复的作用
- 批准号:
10602443 - 财政年份:2020
- 资助金额:
$ 66.53万 - 项目类别:
Role of S-nitrosylation in Transdifferentiation
S-亚硝基化在转分化中的作用
- 批准号:
9906255 - 财政年份:2018
- 资助金额:
$ 66.53万 - 项目类别:
Cell Characterization and Imaging for Regenerative Therapies in Ischemic Diseases
缺血性疾病再生疗法的细胞表征和成像
- 批准号:
8288408 - 财政年份:2012
- 资助金额:
$ 66.53万 - 项目类别:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
烟碱胆碱能通路在早产儿视网膜病变中的作用
- 批准号:
8334482 - 财政年份:2011
- 资助金额:
$ 66.53万 - 项目类别:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
烟碱胆碱能通路在早产儿视网膜病变中的作用
- 批准号:
8733170 - 财政年份:2011
- 资助金额:
$ 66.53万 - 项目类别:
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
烟碱胆碱能通路在早产儿视网膜病变中的作用
- 批准号:
8529537 - 财政年份:2011
- 资助金额:
$ 66.53万 - 项目类别:
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 66.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 66.53万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 66.53万 - 项目类别: